Skip to main content
Top
Published in: International Urology and Nephrology 2/2013

01-04-2013 | Nephrology – Case Report

Mesangial proliferative glomerulonephritis in familial Mediterranean fever patient with E148Q mutation: the first case report

Authors: Eray Eroglu, Ismail Kocyigit, Ozturk Ates, Aydin Unal, Murat Hayri Sipahioglu, Hulya Akgun, Bulent Tokgoz, Oktay Oymak

Published in: International Urology and Nephrology | Issue 2/2013

Login to get access

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive hereditary disease characterized by recurrent attacks of fever, usually accompanied by sterile polyserositis. Although amyloidosis is the most common renal involvement, non-amyloid renal lesions, such as glomerulonephritis, have been described in patients with FMF. In this report, we present the first case of an FMF patient with heterozygous mutation of E148Q, mesangial proliferative glomerulonephritis, and no amyloidosis. While the association of mutation E148Q with renal involvement is still obscure, colchicine treatment is useful in mesangial proliferative glomerulonephritis with FMF.
Literature
1.
go back to reference Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 28:659–664CrossRef Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 28:659–664CrossRef
2.
go back to reference El-Shanti HI (2003) Familial Mediterranean fever and renal disease. Saudi J Kidney Dis Transpl 14:378–385PubMed El-Shanti HI (2003) Familial Mediterranean fever and renal disease. Saudi J Kidney Dis Transpl 14:378–385PubMed
3.
go back to reference Flatau E, Kohn D, Schiller D, Lurie M, Levy E (1982) Schönlein-Henoch syndrome in patients with familial Mediterranean fever. Arthritis Rheum 25:42–47PubMedCrossRef Flatau E, Kohn D, Schiller D, Lurie M, Levy E (1982) Schönlein-Henoch syndrome in patients with familial Mediterranean fever. Arthritis Rheum 25:42–47PubMedCrossRef
4.
go back to reference Ozen S, Ben-Chetrit E, Bakkaloglu A, Gur H, Tinaztepe K, Calguneri M, Turgan C, Turkmen A, Akpolat I, Danaci M, Besbas N, Akpolat T (2001) Polyarteritis nodosa in patients with familial Mediterranean fever(FMF):a concomitant disease or a feature of FMF? Semin Arthritis Rheum 30:281–287PubMedCrossRef Ozen S, Ben-Chetrit E, Bakkaloglu A, Gur H, Tinaztepe K, Calguneri M, Turgan C, Turkmen A, Akpolat I, Danaci M, Besbas N, Akpolat T (2001) Polyarteritis nodosa in patients with familial Mediterranean fever(FMF):a concomitant disease or a feature of FMF? Semin Arthritis Rheum 30:281–287PubMedCrossRef
5.
go back to reference Eliakim M, Rachmilewitz W, Rosenmann R (1970) Renal manifestation in recurrent polyserositis (familial Mediterranean fever). Isr J Med Sci 6:228–245PubMed Eliakim M, Rachmilewitz W, Rosenmann R (1970) Renal manifestation in recurrent polyserositis (familial Mediterranean fever). Isr J Med Sci 6:228–245PubMed
6.
go back to reference Said R, Nasrallah N, Hamzeh Y, Tarawneh M, Al-Khateeb M (1988) Ig A nephropathy in patients with familial Mediterranean fever. Am J Nephrol 8:417–420PubMedCrossRef Said R, Nasrallah N, Hamzeh Y, Tarawneh M, Al-Khateeb M (1988) Ig A nephropathy in patients with familial Mediterranean fever. Am J Nephrol 8:417–420PubMedCrossRef
7.
go back to reference Said R, Hamzeh Y, Tarawneh M, el-Khateeb M, Abdeen M, Shaheen A (1989) Rapid progressive glomerulonephritis in patients with familial Mediterranean fever. Am J Kidney Dis 14:412–416PubMed Said R, Hamzeh Y, Tarawneh M, el-Khateeb M, Abdeen M, Shaheen A (1989) Rapid progressive glomerulonephritis in patients with familial Mediterranean fever. Am J Kidney Dis 14:412–416PubMed
8.
go back to reference Said R, Hamzeh Y, Said S, Tarawneh M, Al-Khateeb M (1992) Spectrum of renal involvement in familial Mediterranean fever. Kidney Int 41:414–419PubMedCrossRef Said R, Hamzeh Y, Said S, Tarawneh M, Al-Khateeb M (1992) Spectrum of renal involvement in familial Mediterranean fever. Kidney Int 41:414–419PubMedCrossRef
9.
go back to reference Said R, Hamzeh Y (1990) IgM nephropathy associated with familial Mediterranean fever. Clin Nephrol 33(5):227–231PubMed Said R, Hamzeh Y (1990) IgM nephropathy associated with familial Mediterranean fever. Clin Nephrol 33(5):227–231PubMed
10.
go back to reference Tekin M, Yalçinkaya F, Tümer N, Cakar N, Koçak H, Ozkaya N, Gençgönül H (1999) Familial Mediterranean fever-renal involvement by diseases other than amyloid. Nephrol Dial Transplant 14(2):475–479PubMedCrossRef Tekin M, Yalçinkaya F, Tümer N, Cakar N, Koçak H, Ozkaya N, Gençgönül H (1999) Familial Mediterranean fever-renal involvement by diseases other than amyloid. Nephrol Dial Transplant 14(2):475–479PubMedCrossRef
11.
go back to reference Akpolat T, Akpolat I, Karagoz F, Yilmaz E, Kandemir B, Ozen S (2004) Familial Mediterranean fever and glomerulonephritis and review of the literature. Rheumatol Int 24:43–45PubMedCrossRef Akpolat T, Akpolat I, Karagoz F, Yilmaz E, Kandemir B, Ozen S (2004) Familial Mediterranean fever and glomerulonephritis and review of the literature. Rheumatol Int 24:43–45PubMedCrossRef
12.
go back to reference Yalcinkaya F, Tumer N (1999) Glomerular lesions other than amyloidosis in patients with familial Mediterranean fever. Nephrol Dial Transplant 14:21–23PubMedCrossRef Yalcinkaya F, Tumer N (1999) Glomerular lesions other than amyloidosis in patients with familial Mediterranean fever. Nephrol Dial Transplant 14:21–23PubMedCrossRef
13.
go back to reference Cagdas DN, Gucer S, Kale G, Duzova A, Ozen S (2005) Familial Mediterranean fever and mesangial proliferative glomerulonephritis: report of a case and review of the literature. Pediatr Nephrol 20(9):1352–1354PubMedCrossRef Cagdas DN, Gucer S, Kale G, Duzova A, Ozen S (2005) Familial Mediterranean fever and mesangial proliferative glomerulonephritis: report of a case and review of the literature. Pediatr Nephrol 20(9):1352–1354PubMedCrossRef
14.
15.
go back to reference Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Hortwiz ME, Mansfield E, Holland SM, O’Shea JJ, Rosenberg HF, Malech HL, Kastner DL (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95:3223–3231PubMed Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Hortwiz ME, Mansfield E, Holland SM, O’Shea JJ, Rosenberg HF, Malech HL, Kastner DL (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95:3223–3231PubMed
16.
go back to reference Babior BM, Matzner Y (1997) The familial Mediterranean fever gene-cloned at last. N Engl J Med 20(337):1548–1549CrossRef Babior BM, Matzner Y (1997) The familial Mediterranean fever gene-cloned at last. N Engl J Med 20(337):1548–1549CrossRef
17.
go back to reference Topaloglu R, Ozaltin F, Yilmaz E, Ozen S, Balci B, Besbas N, Bakkaloglu A (2005) E148Q is a disease-causing MEFV mutation:a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis 64:750–752PubMedCrossRef Topaloglu R, Ozaltin F, Yilmaz E, Ozen S, Balci B, Besbas N, Bakkaloglu A (2005) E148Q is a disease-causing MEFV mutation:a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis 64:750–752PubMedCrossRef
18.
go back to reference Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, Saatci U, Bakkaloglu A, Ozguc M (2001) Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRef Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, Saatci U, Bakkaloglu A, Ozguc M (2001) Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRef
19.
go back to reference Naimushin A, Lidar M, Ben Zvi I, Livneh A (2011) The structural effect of the E148Q MEFV mutation on the pyrin protein: a study using a quantum chemistry model. Isr Med Assoc J 13:199–201PubMed Naimushin A, Lidar M, Ben Zvi I, Livneh A (2011) The structural effect of the E148Q MEFV mutation on the pyrin protein: a study using a quantum chemistry model. Isr Med Assoc J 13:199–201PubMed
20.
21.
go back to reference Westermark P, Benson MD, Buxbaum JN et al (2007) A primer of amyloid nomenclature. Amyloid 14(3):179–183PubMedCrossRef Westermark P, Benson MD, Buxbaum JN et al (2007) A primer of amyloid nomenclature. Amyloid 14(3):179–183PubMedCrossRef
22.
go back to reference Picken MM (2007) New ınsights into systemic amyloidosis: the importance of type diagnosis. Curr Opin Nephrol Hypertens 16(3):196–203PubMedCrossRef Picken MM (2007) New ınsights into systemic amyloidosis: the importance of type diagnosis. Curr Opin Nephrol Hypertens 16(3):196–203PubMedCrossRef
23.
24.
go back to reference Fernandez-Flores A (2010) Comparative study of Congo red fluorescence and immunohistochemistry in cutaneous amyloidosis. Rom J Morphol Embryol 51(4):683–686PubMed Fernandez-Flores A (2010) Comparative study of Congo red fluorescence and immunohistochemistry in cutaneous amyloidosis. Rom J Morphol Embryol 51(4):683–686PubMed
Metadata
Title
Mesangial proliferative glomerulonephritis in familial Mediterranean fever patient with E148Q mutation: the first case report
Authors
Eray Eroglu
Ismail Kocyigit
Ozturk Ates
Aydin Unal
Murat Hayri Sipahioglu
Hulya Akgun
Bulent Tokgoz
Oktay Oymak
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0124-1

Other articles of this Issue 2/2013

International Urology and Nephrology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.